Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of duvelisib when given together
with nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma.
Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Giving duvelisib and nivolumab may work better in treating patients with Richter
syndrome or transformed follicular lymphoma compared to giving duvelisib or nivolumab alone.